Medivir AB (publ) (MVRBF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Medivir AB (publ) (MVRBF) trades at $0.82. Medivir AB (publ) is a Swedish biopharmaceutical company focused on oncology. They develop and market treatments for conditions like labial herpes and cutaneous T-cell lymphoma. Market cap: $45.8M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for MVRBF: MVRBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MVRBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MVRBF: 3/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Medivir AB (publ) (MVRBF) Healthcare & Pipeline Overview
Medivir AB (publ) is a Swedish biopharmaceutical company specializing in oncology, developing treatments for conditions such as labial herpes and cutaneous T-cell lymphoma. Their pipeline includes drug candidates for liver cancer and osteoarthritis, positioning them as a research-driven player in the competitive biotechnology sector.
What Is the Investment Thesis for MVRBF?
Medivir's investment thesis hinges on the successful development and commercialization of its oncology-focused pipeline. Key value drivers include the clinical progress of Remetinostat, MIV-818, and other drug candidates. Positive clinical trial results and regulatory approvals could significantly increase the company's valuation. However, the company's negative profit margin of -2024.1% and gross margin of -1467.1% highlight the financial risks associated with drug development. Upcoming clinical trial data readouts and potential partnerships represent key catalysts. The small market capitalization of $45.8M also presents both an opportunity for significant growth and a risk of volatility.
Based on FMP financials and quantitative analysis
MVRBF Key Highlights
Market capitalization of $45.8M indicates a small-cap company with potential for high growth but also higher risk.
- Negative P/E ratio of -4.51 reflects current losses, typical for biotechnology companies investing heavily in R&D.
- Profit margin of -2024.1% highlights the company's significant expenses related to research and development.
- Gross margin of -1467.1% indicates that the cost of goods sold exceeds revenue, reflecting the current stage of development.
- Beta of 0.36 suggests the stock is less volatile than the overall market.
Who Are MVRBF's Competitors?
MVRBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACOGF Alpha Cognition Inc. | $5.72 | +0.00% | $35.7M | 50 |
| BSTG Biostage, Inc. | $4.03 | +0.75% | $57.8M | 44 |
| DMTTF Small Pharma Inc. | $0.11 | -9.69% | $37.5M | 44 |
| HRPMF Herantis Pharma Oyj | $3.51 | +0.00% | $59.5M | 44 |
| IGXT IntelGenx Technologies Corp. | $0.17 | +0.00% | $29.7M | 47 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MVRBF's Key Strengths?
Focus on oncology, a high-growth therapeutic area.
- Pipeline of drug candidates targeting unmet medical needs.
- Research collaborations with reputable institutions.
- Existing product (Xerclear/Zoviduo) generating revenue.
What Are MVRBF's Weaknesses?
Negative profit and gross margins.
- Small market capitalization, increasing volatility.
- Dependence on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
What Could Drive MVRBF Stock Higher?
Clinical trial data readouts for Remetinostat in 2026 could drive positive stock movement.
- Potential partnerships or licensing agreements for MIV-818 in 2026 could increase investor confidence.
- Continued sales growth of Xerclear/Zoviduo provides a stable revenue stream.
- Advancements in research collaborations with SciLifeLab, Tango Therapeutics, and Ubiquigent Limited may lead to new drug candidates.
- Regulatory progress for any of Medivir's pipeline drugs.
What Are the Key Risks for MVRBF?
Financial-distress signal — its Altman Z-Score of 1.76 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-37.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for key drug candidates could negatively impact the stock price.
- Regulatory delays or rejection of drug applications could hinder growth.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on successful research and development outcomes.
- Limited financial resources may constrain growth opportunities.
What Are the Growth Opportunities for MVRBF?
- Development of MIV-818 for Liver Cancer: Liver cancer represents a significant unmet medical need with a growing market. Successful development and commercialization of MIV-818 could generate substantial revenue for Medivir. Clinical trials are ongoing, with potential data readouts in the next 2-3 years.
- Advancement of Remetinostat for Cutaneous T-Cell Lymphoma: Remetinostat targets a specific type of lymphoma with limited treatment options. Positive clinical trial results could lead to regulatory approval and market exclusivity. The market for cutaneous T-cell lymphoma treatments is expected to grow, driven by increasing incidence rates and the need for more effective therapies. Medivir is actively pursuing clinical trials, with potential for accelerated approval pathways.
- Expansion of Xerclear/Zoviduo Market: Xerclear/Zoviduo, Medivir's treatment for labial herpes, provides a stable revenue stream. Expanding its market reach through strategic partnerships and geographic expansion could boost sales. The global market for herpes simplex virus (HSV) treatments is substantial, and Medivir can leverage its existing product to capture a larger share.
- Strategic Partnerships and Licensing Agreements: Medivir's collaborations with SciLifeLab, Tango Therapeutics, and Ubiquigent Limited provide access to new technologies and research capabilities. These partnerships can accelerate drug discovery and development, increasing the company's pipeline and long-term growth potential. Successful collaborations can lead to new drug candidates and revenue-generating opportunities.
- Development of MIV-711 for Osteoarthritis: Osteoarthritis is a prevalent condition with a large patient population. MIV-711 targets a novel mechanism for treating osteoarthritis, potentially offering a differentiated product in a crowded market. The global osteoarthritis market is projected to grow significantly, driven by an aging population and increasing obesity rates. Clinical trials are underway, with potential for significant market penetration if MIV-711 demonstrates efficacy and safety.
What Are MVRBF's Competitive Advantages?
- Proprietary drug candidates in development.
- Intellectual property protection through patents.
- Established research collaborations with leading institutions.
- Specialized expertise in oncology drug development.
What Does MVRBF Do?
Medivir AB (publ), founded in 1987 and based in Huddinge, Sweden, is a research-based pharmaceutical company focused on developing and marketing treatments primarily in the field of oncology. The company's initial focus was on infectious diseases, particularly HIV, where it played a role in developing protease inhibitors. Over time, Medivir has shifted its focus towards oncology, recognizing the significant unmet needs and growth opportunities in this therapeutic area. Currently, Medivir markets Xerclear (also known as Zoviduo) for the treatment of labial herpes. Its development pipeline includes Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, MIV-818 for liver cancer, MIV-711 for osteoarthritis, and Birinapant and IGM-8444 for solid tumors. Medivir also engages in research collaborations, including a partnership with SciLifeLab for antiviral discovery related to SARS CoV-2 and licensing agreements with Tango Therapeutics and Ubiquigent Limited for preclinical research programs.
What Products and Services Does MVRBF Offer?
- Researches and develops pharmaceutical products.
- Focuses primarily on oncology treatments.
- Markets Xerclear/Zoviduo for labial herpes.
- Develops Remetinostat for cutaneous T-cell lymphoma and basal cell carcinoma.
- Develops MIV-818 for liver cancer treatment.
- Develops MIV-711 for osteoarthritis treatment.
- Engages in research collaborations for antiviral discovery.
- Pursues licensing agreements for preclinical research programs.
How Does MVRBF Make Money?
- Develops pharmaceutical products through internal research and development.
- Out-licenses drug candidates to larger pharmaceutical companies.
- Generates revenue through product sales (e.g., Xerclear/Zoviduo).
- Collaborates with other research institutions and companies to expand its pipeline.
What Industry Does MVRBF Operate In?
Medivir operates in the biotechnology industry, which is characterized by high R&D spending, long development timelines, and significant regulatory hurdles. The oncology market is a major growth driver in the pharmaceutical industry, driven by an aging population and increasing cancer incidence. Competition is intense, with numerous companies developing novel cancer therapies. Medivir's success depends on its ability to differentiate its drug candidates and navigate the complex regulatory landscape. The company's research collaborations and licensing agreements are crucial for expanding its pipeline and accessing new technologies.
Who Are MVRBF's Key Customers?
- Patients suffering from oncology-related diseases.
- Patients with labial herpes.
- Pharmaceutical companies through licensing agreements.
- Healthcare providers who prescribe Medivir's products.
How Medivir AB (publ) Is Valued
Medivir AB (publ) carries a market capitalization of $45.8M, placing it in the micro-cap category.
Company Profile
Medivir AB (publ) operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Huddinge, SE. The company is led by CEO Jens Lindberg. MVRBF has traded publicly since 2010.
Key Financial Metrics
Return on equity for Medivir AB (publ) stands at -37.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -38.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -25.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -22.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Medivir AB (publ)'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.76 places it in the distress zone, a signal of elevated financial risk.
MVRBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on oncology, a high-growth therapeutic area.
- Pipeline of drug candidates targeting unmet medical needs.
- Research collaborations with reputable institutions.
- Existing product (Xerclear/Zoviduo) generating revenue.
Bear Case
- Negative profit and gross margins.
- Small market capitalization, increasing volatility.
- Dependence on successful clinical trial outcomes.
- Limited financial resources compared to larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MVRBF Latest News
No recent news available for MVRBF.
MVRBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MVRBF.
Price Targets
Wall Street price target analysis for MVRBF.
MVRBF MoonshotScore
What does this score mean?
The MoonshotScore rates MVRBF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jens Lindberg
CEO
Jens Lindberg serves as the CEO of Medivir AB (publ). His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions in commercial operations, business development, and strategic planning. Lindberg's expertise spans across multiple therapeutic areas, including oncology and infectious diseases. His career reflects a strong focus on driving growth and innovation within the healthcare sector.
Track Record: Since becoming CEO, Jens Lindberg has focused on advancing Medivir's oncology pipeline and strengthening its research collaborations. Key milestones under his leadership include the progression of Remetinostat and MIV-818 through clinical trials and the expansion of partnerships with SciLifeLab, Tango Therapeutics and Ubiquigent Limited. He has also overseen the commercialization of Xerclear/Zoviduo and efforts to expand its market reach.
MVRBF OTC Market Information
The OTC Other tier, where MVRBF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. This tier typically includes companies with higher risk profiles, including those that are early-stage, distressed, or have regulatory issues. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in MVRBF.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- The OTC Other tier designation indicates a higher risk profile compared to exchange-listed stocks.
- Potential for fraud or manipulation is higher in the OTC market.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Check for any red flags or warning signs, such as pending lawsuits or regulatory investigations.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 1987.
- Medivir has existing products on the market (Xerclear/Zoviduo).
- The company has research collaborations with reputable institutions (SciLifeLab).
- Medivir has a pipeline of drug candidates in clinical development.
- CEO Jens Lindberg has experience in the pharmaceutical industry.
Medivir AB (publ) Healthcare Stock: Key Questions Answered
What does Medivir AB (publ) do?
Medivir AB (publ) is a Swedish biopharmaceutical company that focuses on researching, developing, and marketing pharmaceutical products, primarily in the field of oncology. The company's lead product is Xerclear/Zoviduo, used for the treatment of labial herpes.
What do analysts say about MVRBF stock?
Analyst coverage of MVRBF is limited due to its small market capitalization and OTC listing. Key valuation metrics, such as P/E ratio, are currently negative, reflecting the company's ongoing losses. Growth considerations center on the successful development and commercialization of its pipeline drugs, particularly Remetinostat and MIV-818. Positive clinical trial results and regulatory approvals are critical for driving future growth.
What are the main risks for MVRBF?
The main risks for Medivir AB (publ) include clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. The company's financial performance is heavily dependent on the successful development and commercialization of its pipeline drugs. Clinical trial failures or regulatory delays could significantly impact the company's prospects.
What are the key factors to evaluate for MVRBF?
Evaluate MVRBF on fundamentals, analyst consensus, and risk factors. Medivir's investment thesis hinges on the successful development and commercialization of its oncology-focused pipeline. Not financial advice.
How frequently does MVRBF data refresh on this page?
MVRBF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MVRBF's recent stock price performance?
Medivir AB (publ) (MVRBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on oncology, a high-growth therapeutic area. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MVRBF overvalued or undervalued right now?
Medivir AB (publ) (MVRBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MVRBF before investing?
Before investing in Medivir AB (publ) (MVRBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending for MVRBF.